July 16, 2021 10:40 AM EDTUpdated 04:12 PM

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff

Kathy Wong

Editor

Alex Hoffman

Copy Chief

→ Covid-19 variants have marred the effectiveness of Eli Lilly and AbCellera’s bamlanivimab to such an extent that the US government stopped using the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff

Kathy Wong

Editor

Alex Hoffman

Copy Chief

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Regeneron plans to buy 23andMe for $256M

David Liu, Sam Sternberg unveil new way to insert big genes in human cells

Prime Medicine sidelines only clinical program, replaces CEO and lays off some staff

Intellia's CRISPR therapy likely causes 'permanent' gene knockdown in ATTR amyloidosis

Exclusive: CellCentric collects $120M to treat multiple myeloma with a capsule

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Eli Lil­ly part­ner Ab­Cellera finds a CBO in the face of bam­lanivimab strug­gles; Fi­bro­Gen's next CSO walks in­to rox­adu­s­tat re­buff

Editor

Copy Chief

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff